Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly
dc.contributor.author | Greenstein, Ellen | en_US |
dc.contributor.author | Ho, J. Jean | en_US |
dc.contributor.author | Boyajy, Louis D. | en_US |
dc.contributor.author | Barkan, Ariel L. | en_US |
dc.date.accessioned | 2006-09-11T14:46:13Z | |
dc.date.available | 2006-09-11T14:46:13Z | |
dc.date.issued | 1993-02 | en_US |
dc.identifier.citation | Ho, J. Jean; Boyajy, Louis D.; Greenstein, Ellen; Barkan, Ariel L.; (1993). "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Digestive Diseases and Sciences 38(2): 309-315. <http://hdl.handle.net/2027.42/44417> | en_US |
dc.identifier.issn | 0163-2116 | en_US |
dc.identifier.issn | 1573-2568 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44417 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8425442&dopt=citation | en_US |
dc.description.abstract | The adverse gastrointestinal effects of octreotide, a synthetic analog of somatostatin, have not been fully elucidated. Low-dose octreotide frequently causes adverse gastrointestinal symptoms in normal individuals. We investigated the adverse gastrointestinal effects of high-dose octreotide, which is required for the normalization of growth hormone hypersecretion in some patients with acromegaly. Patients with acromegaly ( N =8) were treated with octreotide, 450 μg/day, then 1500 μg/day for two months at each dosage. Carbohydrate absorption was assessed using the d -xylose test, and fat absorption using fecal fat excretion and serum carotene concentrations, at baseline, at each dosage of octreotide, and after one month of washout. Ultrasonography was used to monitor for cholelithiasis. Growth hormone and insulin-like growth factor-I concentrations were significantly suppressed at both dosages. Adverse gastrointestinal symptoms were mild and transient. d -Xylose absorption remained normal at each dosage and after one month of washout. Fecal fat excretion increased from 7±2 to 12±2 g/24 hr ( P <0.05) after the higher dosage and resumed baseline levels after the washout. Mean fasting serum carotene levels remained normal, and carotene loading test (15,000 units three times a day for three days) was unreliable in identifying patients with high fecal fat. No new cholelithiasis was detected by ultrasonography. One of two patients with preexisting cholelithiasis developed biliary colic several days after the treatment period. Although steatorrhea was common, small intestinal absorptive capacity was otherwise unchanged by four months of high-dose octreotide treatment, which significantly suppressed growth hormone secretion in acromegalic patients. | en_US |
dc.format.extent | 791651 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Gastroenterology | en_US |
dc.subject.other | Xylose | en_US |
dc.subject.other | Adverse Effects | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Hepatology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Transplant Surgery | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Intestinal Absorption | en_US |
dc.subject.other | Octreotide | en_US |
dc.subject.other | Acromegaly | en_US |
dc.subject.other | Fat | en_US |
dc.subject.other | Carotene | en_US |
dc.subject.other | Cholelithiasis | en_US |
dc.title | Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of Veterans Affairs Medical Center and University of Michigan Medical Center, 48109, Ann Arbor, Michigan; Sandoz Pharmaceuticals Corporation, 07936, East Hanover, New Jersey | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of Veterans Affairs Medical Center and University of Michigan Medical Center, 48109, Ann Arbor, Michigan; Sandoz Pharmaceuticals Corporation, 07936, East Hanover, New Jersey | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of Veterans Affairs Medical Center and University of Michigan Medical Center, 48109, Ann Arbor, Michigan; Sandoz Pharmaceuticals Corporation, 07936, East Hanover, New Jersey | en_US |
dc.contributor.affiliationum | Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of Veterans Affairs Medical Center and University of Michigan Medical Center, 48109, Ann Arbor, Michigan; Sandoz Pharmaceuticals Corporation, 07936, East Hanover, New Jersey; Division of Endocrinology and Metabolism, University of Michigan Medical Center, 3920 Taubman Center, Box 0354, 48109-0354, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8425442 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44417/1/10620_2005_Article_BF01307549.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF01307549 | en_US |
dc.identifier.source | Digestive Diseases and Sciences | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.